Business
Frequency Therapeutics Provides Business Updates and Reports First Quarter 2020 Financial Results
Phase 2a Study of FX-322 for Sensorineural Hearing Loss Continues Enrollment at Multiple Sites Shares Top-Line Data from Exploratory Clinical Study
About this update from Korro Bio, Inc.
[{"type":"text","content":"\nPhase 2a Study of FX-322 for Sensorineural Hearing Loss Continues Enrollment at Multiple Sites\n\n\nShares Top-Line Data from Exploratory Clinical Study Confirming Delivery of FX-322 to the Cochlea \n\n WOBURN, Mass.--(BUSINESS WIRE)--\nFrequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the first quarter ending March 31, 2020.\n\n\n“Our Phase 2a study of FX-322 for sensorineural hearing loss continues to enroll subjects at a number of clinical sites, despite challenges from the COVID-19 pandemic. Overall, we are pleased with our progress and we deeply appreciate the work of our investigators, site staff and the engagement of the patients participating in the study during this challenging period,” said Frequency Therapeutics Chief Executive Officer David L. Lucchino.\n\n\n“Today, we also shared top-line data from a new exploratory clinical study that showed in all study patients that FX-322 was delivered to the intended target within the cochlea at drug levels that could be directly measured. Further, concentrations of FX-322 were predicted to be therapeutically active. With these new data, we have now collectively observed three key elements in FX-322’s clinical development trajectory: effective delivery to the target tissue, a favorable safety profile, and clinically meaningful improvements in hearing function.\n\n\n“The cochlea is one of the most privileged and difficult-to-reach sites in the body. Quantifying drug concentrations of a potential restorative medicine in the cochlea represents an important advance in inner-ear drug discovery,” Mr. Lucchino continued. “This advance furthers Frequency’s leadership in hearing regeneration and our enthusiasm for the potential of FX-322 to benefit the millions of individuals suffering from sensorineural hearing loss.”\n\n\nRecent Program and Business Updates\n\n\nFX-322 Phase 2a Study for Sensorineural Hearing Loss: The FX-322 Phase 2a study is a randomized, double-blind, placebo-controlled, single- and repeat-dose study that may enroll up to 96 patients aged 18 to 65 with stable sensorineural hearing loss (SNHL). The objectives of the Phase 2a study are to further est...